Immunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development

被引：26
作者：
Eggermont, Alexander M. M. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, NL-3075 EA Rotterdam, Netherlands
来源：
CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 22期
关键词：
MELANOMA; IMMUNOTHERAPY; SURVIVAL; TRIAL;
D O I：
10.1158/1078-0432.CCR-09-2377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Three articles in this issue of Clinical Cancer Research show how multiple vaccinations can lead to immunosuppression. Moreover, two studies in patients show that granulocyte macrophage colony-stimulating factor (GM-CSF) as an adjuvant immunostimulant to different kind of vaccines can lead to adverse outcome in terms of relapse-free and overall survival. Modulation of regulatory T-cell activity may be required to overcome this outcome and may be crucial for the successful development of therapeutic vaccines. (Clin Cancer Res 2009;15(22):6745-7)
引用
收藏
页码：6745 / 6747
页数：3
相关论文
共 18 条
  • [1] Therapeutic vaccines in solid tumours: Can they be harmful?
    Eggermonf, Alexander M. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (12) : 2087 - 2090
  • [2] EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results
    Eggermont, A. M.
    Suciu, S.
    Ruka, W.
    Marsden, J.
    Testori, A.
    Corrie, P.
    Aamdal, S.
    Ascierto, P. A.
    Patel, P.
    Spatz, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Melanoma and Immunotherapy
    Eggermont, Alexander M. M.
    Schadendorf, Dirk
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (03) : 547 - +
  • [4] Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Eggermont, AMM
    Kirkwood, JM
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (12) : 1825 - 1836
  • [5] Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
    Faries, Mark B.
    Hsueh, Eddy C.
    Ye, Xing
    Hoban, Mary
    Morton, Donald L.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (22) : 7029 - 7035
  • [6] A clinical development paradigm for cancer vaccines and related biologics
    Hoos, Axel
    Parmiani, Giorgio
    Hege, Kristen
    Sznol, Mario
    Loibner, Hans
    Eggermont, Alexander
    Urba, Walter
    Blumenstein, Brent
    Sacks, Natalie
    Keilholz, Ulrich
    Nichol, Geoffrey
    [J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (01) : 1 - 15
  • [7] Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
    Hsueh, EC
    Essner, R
    Foshag, LJ
    Ollila, DW
    Gammon, G
    O'Day, SJ
    Boasberg, PD
    Stern, SL
    Ye, X
    Morton, DL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) : 4549 - 4554
  • [8] High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
    Kirkwood, JM
    Ibrahim, JG
    Sosman, JA
    Sondak, VK
    Agarwala, SS
    Ernstoff, MS
    Rao, U
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) : 2370 - 2380
  • [9] Partial CD4 Depletion Reduces Regulatory T Cells Induced by Multiple Vaccinations and Restores Therapeutic Efficacy
    LaCelle, Michael G.
    Jensen, Shawn M.
    Fox, Bernard A.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (22) : 6881 - 6890
  • [10] The role of vaccine therapy in the treatment of melanoma
    Lens, Marko
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (03) : 315 - 323
12